Abstract
To provide an early estimate of 2011/12 influenza vaccine effectiveness (VE), we conducted a multicentre case-control study based on seven sentinel surveillance networks. We included influenza-like illness cases up to week 7/2012 from the vaccination target groups, swabbed less than eight days after symptom onset. Laboratory-confirmed influenza A(H3) cases were compared to negative controls. Adjusted VE was 43% (95% confidence interval: -0.4 to 67.7), suggesting low to moderate VE against influenza A(H3) in the early 2011/12 season.
Highlights
In the context of the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Network we estimated the effectiveness of the 2011/12 trivalent vaccine against medically attended influenza-like illness (ILI) that was laboratory-confirmed as influenza
We provide early season estimates of the effectiveness of the 2011/12 vaccine against influenza A(H3) virus among those subpopulations identified as target groups for vaccination in the respective countries (Table 1) [3,4,5,6,7,8,9,10]
In each country we included ILI patients who presented to the practitioner up to the end of week 7/2012 who belonged to a target group for vaccination, with onset of symptoms more than 14 days after the start of national or regional influenza vaccination campaigns
Summary
In the context of the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Network we estimated the effectiveness of the 2011/12 trivalent vaccine against medically attended influenza-like illness (ILI) that was laboratory-confirmed as influenza. Data were collected from week 48/2011 to week 7/2012 During these 12 weeks of data collection, 867 (92.7%) of 935 laboratory-confirmed influenza cases recruited in the study were identified as influenza A(H3). This finding was consistent with data from the Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe: of the 11,159 viruses detected from week 40/2011 to week 7/2012, 95.9% were influenza type A, and of 6,238 influenza A viruses subtyped, 97.5% were influenza A(H3) [2]. We provide early season estimates of the effectiveness of the 2011/12 vaccine against influenza A(H3) virus among those subpopulations identified as target groups for vaccination in the respective countries (Table 1) [3,4,5,6,7,8,9,10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
